Baxter To Acquire Continuous Renal Replacement Therapy Business From Edwards Lifesciences
Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards’ hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals.
More: continued here
Filed under: Pharma Industry on June 30th, 2009
You must be logged in to post a comment.